- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | Genelux Corporation: Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi-Vec in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 22.06. | GENELUX Corp - 8-K, Current Report | 2 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 08.05. | Genelux GAAP EPS of -$0.20 | 1 | Seeking Alpha | ||
| 07.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 19.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Genelux GAAP EPS of -$0.86 misses by $0.01 | 2 | Seeking Alpha | ||
| 19.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 742 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| 19.03. | GENELUX Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 823 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 418 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 238 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen | |
| 07.08.25 | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 265 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,595 | +4,12 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,489 | +0,68 % | InflaRx NV im Blickpunkt: Die Entwicklung die jetzt niemand auf dem Schirm hat - Meine klare Einschätzung dazu | ||
| INTELLIA THERAPEUTICS | 9,300 | -3,43 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| IBIO | 1,172 | -3,86 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,679 | +7,56 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IMMUNITYBIO | 6,220 | -3,86 % | ImmunityBio, Inc. - 8-K, Current Report | ||
| IMMATICS | 7,900 | 0,00 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,377 | -4,90 % | MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF | Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered... ► Artikel lesen | |
| IMMUNIC | 12,465 | +2,42 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,590 | -11,90 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 | ||
| MOLECULIN BIOTECH | 0,395 | -61,24 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,700 | +1,45 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| CYBIN | 6,880 | -2,41 % | Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule | Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program
Participant rollover is ongoing into the EXTEND long-term study generating... ► Artikel lesen | |
| GENPREX | 5,820 | -18,26 % | Genprex, Inc. - 8-K, Current Report | ||
| MACROGENICS | 3,160 | -4,24 % | Citizens reiterates MacroGenics stock rating ahead of ESMO data |
GENELUX CORPORATION gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,64 % bei einem Aktienkurs von 2,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.